|
Originally published In Press as doi:10.1074/jbc.M106670200 on January 2, 2002
J. Biol. Chem., Vol. 277, Issue 11, 9387-9394, March 15, 2002
17 -Estradiol Modulates Mechanical Strain-induced
MAPK Activation in Mesangial Cells*
Joan
Krepinsky §,
Alistair J.
Ingram¶ ,
Leighton
James ,
Hao
Ly ,
Kerri
Thai¶,
Daniel C.
Cattran ,
Judith A.
Miller , and
James W.
Scholey **
From the Department of Medicine, University of
Toronto, Toronto, Ontario M5G 2C4, Canada and the
¶ Department of Medicine, McMaster University,
Hamilton, Ontario L8N 1Y2, Canada
Received for publication, July 16, 2001, and in revised form, December 31, 2001
 |
ABSTRACT |
Gender is an important determinant of clinical
outcome across a broad spectrum of kidney diseases, but the
mechanism(s) responsible for the protective effect of female gender
have not been fully elucidated. Remnant kidney glomerular injury is
limited in female rats compared with male rats despite similar
elevations in glomerular capillary pressure. In vitro,
mechanical strain leads to the activation of p44/42
mitogen-activated kinase (p44/42 MAPK) and Jun N-terminal kinase/stress-activated protein kinase (SAPK) in glomerular mesangial cells (MC). Accordingly, we studied the effect of 17 -estradiol on
mechanical strain-induced signal transduction in MC. Exposure of
MC to mechanical strain increased p44/42 MAPK activation (3-fold) and
SAPK activation (2.5-fold), and kinase activation was inhibited by
pretreatment with 17 -estradiol (10 8 to
10 11 M) for 24 h in a
dose-dependent manner. Mechanical strain-induced nuclear
translocation of p44/42 MAPK and SAPK and nuclear protein binding to
AP-1 were also attenuated by 17 -estradiol. The inhibitory effects of
17 -estradiol were not reproduced by the cell-impermeable estrogen,
BSA/17 -estradiol, nor did preincubation with 17 -estradiol lead to actin cytoskeleton disassembly or impaired stress fiber formation. However, 17 -estradiol did increase base-line levels of
the dual specificity phosphatase MKP-1. The inhibitory effects of
17 -estradiol on p44/42 MAPK activation and SAPK activation, translocation, and AP-1 binding were all abrogated by the estrogen receptor antagonist, ICI-182,780. We conclude that attenuation of mechanical strain-induced MAPK activation by 17 -estradiol is
dependent on intracellular estrogen receptor. The attenuation of
stretch-induced kinase activation may be due, at least in part, to an
effect of 17 -estradiol on MKP-1 expression. Together, these findings
add insight into the protective effect of gender on renal disease progression.
 |
INTRODUCTION |
Chronic renal disease is relentlessly progressive after loss of a
critical fraction of nephrons, and intraglomerular hemodynamics play a
central role in the decline to end stage renal disease in this setting
(1). This is most directly apparent in the ability of agents that
prevent rises in intraglomerular pressure, such as angiotensin
antagonists, to delay disease progression (2). More recently, other
factors that impact progression of chronic renal disease have also been
identified. Interestingly, it has been reported that females progress
more slowly than males, and a protective effect of gender has been
hypothesized (3). In support of this, estrogen has been found to limit
both mesangial cell (MC) proliferation and matrix protein production
(4). It was reported that acute estrogen exposure activated p42/44 (extracellular signal-regulated kinase 1/2) mitogen-activated protein
kinase (MAPK)1 in resting MC
and that this resulted in suppression of matrix protein synthesis (5).
However, these studies also demonstrated that preincubation with
estrogen antagonized p44/42 MAPK activation in response to angiotensin
II or platelet-derived growth factor (5). Since estrogen exposure
in vivo is not an acute event, it is probable that this
latter observation is the more relevant.
MC are positioned as architectural supports for capillary loops and are
therefore exposed in vivo to pulsatile stretch/relaxation (6). The effects of mechanical forces on MC in vitro can be modeled by culturing cells in wells with deformable bottoms, with application of a vacuum to the well to generate alternating cycles of
strain and relaxation. Induction of mRNA for c-fos, the
proto-oncogene and AP-1 transcription factor component, maximally at 30 min was the paradigmatic response observed with this system (6). MC proliferation (7) and collagenous and noncollagenous extracellular matrix protein synthesis, the sine qua non of sclerotic
injury, are observed after 48 h of pulsatile stretch-relaxation
(8).
We and others have studied the link between mechanical stress and
c-fos induction in stressed MC (9, 10). We demonstrated increases in all three canonical MAPK pathways in response to strain
(10) and demonstrated that MC proliferation in this setting was
associated with MAPK activity (10, 11). We further showed that the
ability of stretch to activate p44/42 MAPK was dependent on the actin
cytoskeleton (12). Both p44/42 MAPK and SAPK are well recognized to lie
upstream of AP-1 (13). In support of the importance of p44/42 MAPK/AP-1
signaling, glomerular p44/42 MAPK activation and AP-1 nuclear protein
binding were shown in response to angiotensin II infusion (14). AP-1
activation may be important in the pathogenesis of glomerular
sclerosis, since it has been shown to mediate transforming growth
factor- 1 induction (15).
Given the apparent protective effect of female gender on renal disease
progression, the ability of preincubation with estrogen to
down-regulate growth factor-induced p44/42 MAPK activity, and the
induction of MAPK by MC stress, we postulated that estrogen was likely
to inhibit MC MAPK activation in stretched cells. Accordingly, we
studied the effect of estrogen on stretch-induced activation of p44/42
MAPK and SAPK in MC.
 |
MATERIALS AND METHODS |
Cell Culture
Sprague-Dawley rat MC were cultured in Dulbecco's modified
Eagle's medium supplemented with 20% fetal calf serum
(Invitrogen), streptomycin (100 µg/ml), penicillin (100 units/ml), and 2 mM glutamine at 37 °C in 95% air, 5%
CO2. Experiments were carried out in cells between passages
15 and 20.
Application of Strain/Relaxation
MC (5 × 104/well) were plated on six-well
plates with flexible bottoms coated with bovine type I collagen
(Flexcell International Corp., McKeesport, PA). Cells were grown to
confluence for 72 h and then rendered quiescent by incubation for
24 h in Dulbecco's modified Eagle's medium with 0.5% fetal calf
serum. To characterize the time of maximum response, cells were
initially exposed to cycles of strain/relaxation for periods of 2, 5, 10, 30, and 60 min, generated by a cyclic vacuum produced by a
computer-driven system (Flexercell Strain Unit 2000; Flexcell). To
establish if more than one peak of MAPK activation exists, a longer
time course with stretch exposure for 5, 10, 30, and 60 min and 4 and
24 h was conducted. For all experiments, plates were exposed to
continuous cycles of strain/relaxation, each cycle consisting of
0.5 s of strain and 0.5 s of relaxation, for a total of 60 cycles/min. Initially, vacuum pressures used were 10 to 27 kPa,
inducing a 16-28% elongation in the diameter of the surface.
Subsequent experiments were performed at the time and strain level of
maximal response, 10 min and 27 kPa (average 28% elongation in
diameter of the plates).
For experiments studying estrogen effects, 17 -estradiol or the
cell-impermeable 17 -estradiol/bovine serum albumin (BSA) (both from
Sigma) were added at the indicated concentrations 24 h prior to
the initiation of stretch protocols. ICI-182,780 (Tocris Cookson, St.
Louis, MO), a high affinity estrogen receptor antagonist, was added
24 h prior to the initiation of stretch protocols where indicated.
MAPK Phosphorylation and Activities
Protein Isolation and Western Blotting--
Initially, the time
course and concentration dependence of MAPK activities in response to
stretch were studied, and subsequent experiments were performed at 27
kPa at 10 min. Cultures were serum-starved overnight prior to stretch
protocols. After stretch protocols with or without estrogen and
inhibitors, medium was removed, and the cells were washed once with
ice-cold PBS. Cells were lysed in a buffer containing 20 mM
Tris-HCl (pH 7.5), 150 mM NaCl, 1% Triton X-100, 1 mM EDTA, 1 mM EGTA, 2.5 mM sodium pyrophosphate, 1 mM -glycerophosphate, 2 mM
DTT, 1 mM Na3VO4, 1 mM
phenylmethylsulfonyl fluoride, 1 µg/ml leupeptin, and 20 µg/ml
aprotinin. Cell lysate (50 µg/lane) was separated by SDS-PAGE and
transferred onto Immobilon-P membranes (Millipore Corp.). After
blocking with 5% skim milk, primary antibodies were applied. The
following antibodies were used for immunoblots: anti- p42/44 extracellular signal-regulated kinase (1:500), anti-SAPK (1:500), anti-phospho-p44/42 extracellular signal-regulated kinase
(Thr202/Tyr204, 1:1000), anti-phospho-SAPK
(Thr183/Tyr185, 1:1000) (New England Biolabs),
anti-MKP-1 (1:1000; Santa Cruz Biotechnology, Inc.), anti-MKP-3 (1:100,
Santa Cruz Biotechnology), and anti- -actin (1:5000; Sigma). Signals
were detected by use of an ECL Western blotting Kit (Amersham
Biosciences, Inc.).
Activity Assays--
After protein isolation from total cell
lysate as above, 200 µg of total protein was then incubated with
p44/42 MAPK (Thr202/Tyr204) monoclonal antibody
(1:200) New England Biolabs) with gentle rocking overnight at 4 °C.
Protein A-Sepharose beads (20 µl of 50% beads) were then
added, and the gentle rocking continued an additional 3 h. Lysate
was then microcentrifuged for 30 s at 14,000 rpm to recover the
beads, and the pellet was washed twice with 0.5 ml of 1× lysis buffer.
For kinase assays, after immunoprecipitation, pellets were washed twice
with 0.5 ml of kinase buffer (25 mM Tris, 5 mM
-glycerophosphate, 2 mM DTT, 0.1 mM sodium
orthovanadate, 10 mM MgCl2). p44/42 MAPK
activity was then performed by suspending the pellet in 50 µl of 1×
kinase buffer, with 200 µM ATP and 2 µg of Elk1 fusion
protein. After incubation for 30 min at 30 °C, the reaction was
terminated with 25 µM 3× SDS sample buffer
(187.5 mM Tris-HCl (pH 6.8), 6% (w/v) SDS, 30% glycerol,
150 mM DTT, 0.3% (w/v) bromphenol blue), boiled for 5 min,
vortexed, and then microcentrifuged for 2 min. 20 µl of sample was
then run on a SDS-PAGE gel. Membranes were then blotted to
nitrocellulose, incubated overnight at 4 °C with phosphospecific
anti-Elk (Ser383) antibody (1:1000) and visualized as
above. To assay SAPK activity, a "pull-down" SAPK assay was
employed. After protein isolation as above, 2 µg of c-Jun fusion
protein beads (New England Biolabs) were added to 250 µg of cell
lysate protein and incubated overnight at 4 °C. Lysate was then
centrifuged for 30 s to recover the beads and washed twice with
1× lysis buffer. The pellet was then resuspended in kinase buffer and
boiled as previously. 20 µl of sample was run on a 12% SDS-PAGE gel.
Blotting and detection were performed as above, except that the primary
antibody was phosphospecific c-Jun (Ser63) at 1:1000 dilution.
ER Immunoblotting--
ER expression in response to
17 -estradiol was assessed in unstretched cells by immunoblotting
exactly as above with monoclonal mouse anti-ER (1:500; Affinity
Bioreagents) as the primary antibody.
Fluorescence Microscopy
MAPK Nuclear Translocation--
After each strain protocol with
or without estrogen and inhibitors, cells were washed three times with
PBS and fixed with 3.7% formaldehyde (300 µl/well) for 10 min at
room temperature. Cells were washed three times with PBS and then
permeabilized in 100% methanol for 5 min at 20 °C, washed again
with PBS and incubated with anti-phospho-p44/42 MAPK or
anti-phospho-SAPK (both 1:50 dilution in PBS) for 30 min at room
temperature. Cells were washed three times in PBS and incubated with an
Alexa 488 goat anti-rabbit IgG (H + L) conjugate (Molecular Probes,
Inc., Eugene, OR) 1:50 dilution in PBS for 30 min at room temperature
in the dark. Cells were washed and then mounted by removing the
flexible base from each well and placing it directly on a glass slide
using one drop of anti-fade mount medium (Slow Fade, Molecular
Probe). A drop of mount medium was then placed on top of the
cells and covered with a glass slip. Slides were stored at 4 °C in
the dark until confocal laser-scanning microscopy was performed using a Bio-Rad MRC-600 confocal microscope within 10 days.
F-actin Staining--
MC were fixed with formaldehyde exactly as
above and then permeabilized by dipping in acetone for 5 min at
20 °C. Subsequently, Texas Red phalloidin solution (Molecular
Probes) was applied for 20 min at room temperature. Cells were then
washed, mounted, and analyzed exactly as above.
Nuclear Protein Binding to AP-1 Consensus Sequences--
After
each strain protocol, MC were washed in cold PBS, and nuclear extracts
were prepared by lysis in hypotonic buffer (20 mM Hepes, pH
7.9, 1 mM EDTA, 1 mM EGTA, 20 mM
NaF, 1 mM Na3VO4, 1 mM
Na4P2O7, 1 mM DTT, 0.5 mM phenylmethylsulfonyl fluoride, 1 µg/ml aprotinin, 1 µg/ml leupeptin, 1 µg/ml pepstatin A, 0.6% Nonidet P-40),
homogenized, and sedimented at 16,000 × g for 20 min
at 4 °C. Pelleted nuclei were resuspended in hypotonic buffer containing 0.42 M NaCl2, 20% glycerol and
rotated for 30 min at 4 °C. After centrifugation for 20 min at
16,000 × g, the supernatant containing nuclear
proteins was collected, and protein concentration was measured with the
Bio-Rad assay kit.
Radiolabeled AP-1 consensus oligonucleotides were prepared by
incubating 2 µl of consensus oligonucleotide (1.75 pmol/µl; Promega), 1 µl of T4 polynucleotide kinase 10× buffer, 1 µl of [ -32P]ATP (3,000 Ci/ml) (Amersham Biosciences), and 5 µl of nuclease-free water for 10 min at 37 °C. The reaction was
stopped by adding 1 µl of 0.5 M EDTA. Unlabeled
[32P]ATP was removed from the oligonucleotide mixture
with Chroma-Spin STE-10 columns (CLONTECH, Palo
Alto, CA).
Nuclear proteins (3 µg) were incubated with 2 µg of
poly(dI-dC)·poly(dI·dC) (Amersham Biosciences) in binding buffer
(20 mM HEPES, pH 7.9, 1.8 mM MgCl2,
2 mM DTT, 0.5 EDTA, 0.5 mg/ml BSA) for 30 min at room
temperature and then reacted with radiolabeled consensus
oligonucleotides at room temperature for 20 min (50,000-100,000 cpm).
Reaction mixtures were electrophoresed in a 6% polyacrylamide gel and
autoradiographed. Competition experiments were performed with a
100-fold excess of unlabeled AP-1 consensus oligonucleotides.
RNA Isolation and Semiquantitative Reverse Transcriptase
(RT)-PCR
Total RNA from MC was isolated by the single step method of
Chomczynski and Sacchi (16) as we have described (17). Isolated RNA was
stored in diethyl pyrocarbonate-treated water at 80 °C. The purity
and concentration was determined by measuring the optical density at
260 and 280 nm prior to use. The
A260/A280 ratio ranged from 1.75-1.95.
Semiquantitative RT-PCR was performed as previously reported (17). The
specific primer sequences were as follows: -actin, 5'-AAC CCT AAG
GCC AAC CGT GAA AAG-3' and 3'-TCA TGA GGT AGT CTG TCA GGT C-5';
c-fos, 5'-GAGCTGACAGATACGCTCCAAGCG-3' and
5'-CGGGTCTGCTGCAATTAAGGAAGGGAAAACCCAA-3'.
For amplification, 2.5 µl of the RT product was mixed with 7.5 µl
of PCR mix containing 0.1 µM of each of the primer pairs and 2 units of Taq polymerase. The sample was placed onto a
PerkinElmer DNA thermal cycler (model 480) and heated to 94 °C for 4 min prior to the application of temperature cycles. -Actin was
co-amplified to standardize the amount of RNA subjected to reverse
transcription. The temperature cycle for amplification was as follows:
1) denaturing at 94 °C for 60 s, 2) cooling-annealing at
55 °C for 30 s; and 3) heat extension at 72 °C for 60 s. PCR products plateaued at 28 cycles; therefore, 25 cycles was chosen
for the final amplification. PCR products were separated on 1% agarose
gel containing ethidium bromide, photographed, and quantitated with a
GS 300 transmittance/reflectance scanning densitometer (Hoefer
Scientific Instruments) utilizing a MacIntosh Class II (System 7.0)
computer and Dynamax HPLC Method Management (version 1.2) software.
Statistical Analysis
Statistical analyses were performed with the INSTAT statistical
package (GraphPad Software Inc., San Diego, CA). The difference between
means was analyzed using the Bonferroni Multiple comparison test.
Significance was defined as p < 0.05.
 |
RESULTS |
Estrogen Dose-dependently Attenuates Strain-induced
MAPK Activity in MC--
As in previous studies, we observed time- and
magnitude-dependent strain activation of p44/42 MAPK and
SAPK (10, 12), maximally at 5-20 min and at 27 kPa pressure (data
not shown). Only one peak of activation for both kinases was observed
over a 24-h period of strain at 27 kPa (Fig.
1). Preincubation for 24 h with
17 -estradiol dose-dependently inhibited the activity of
both MAPK cascades at 10 min of 27 kPa stretch (Fig.
2, A and B),
maximally at 10 8 M. Consequently, subsequent
studies used this concentration of 17 -estradiol and stretch was
applied for 10 min at 27 kPa and 60 Hz.

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 1.
Time course of stretch-induced p44/42 MAPK
and SAPK activation. Serum-starved MC were exposed to a 27-kPa
stretch at 60 Hz for the indicated times. Total cell lysates were
immunoblotted with antibodies specific for phosphorylated p44/42 MAPK
(A and B) and phosphorylated SAPK (C
and D). Densitometry data are shown for each
(n = 3).
|
|

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 2.
Stretch-induced p44/42 MAPK and SAPK activity
in MC is prevented by 17 -estradiol.
A, serum-starved MC were incubated with 17 -estradiol
(10 8 to 10 11 M) for 24 h
and then exposed to a 27-kPa stretch at 60 Hz for 10 min. p44/42 MAPK
activity in total cell lysate was assayed by in vitro
phosphorylation of a target Elk-1 protein and immunoblotting with an
antibody specifically recognizing phosphorylated Elk-1
(Ser383) as described under "Materials and Methods."
Total p44/42 MAPK is shown above. The data are shown
graphically below (n = 3). B, MC
were treated as in A, and SAPK activity in total cell lysate
was measured by in vitro phosphorylation of a target
c-Jun protein, which was visualized by immunoblotting with an
antibody specific for phosphorylated c-Jun (Ser63).
Total SAPK protein is shown above. The data are shown
graphically below (n = 3).
|
|
Cell Entry and Time Are Required for the Effect of
Estrogen--
It has become apparent in recent years that both cell
surface and cytoplasmic estrogen receptors exist, and some of the
cardioprotective effects of estrogen have been ascribed to the former.
In the most well studied example, 17 -estradiol induced endothelial
nitric-oxide synthase through rapid (5 min) MAPK activation (18, 19).
Similar rapid actions of estrogen have been observed in neuronal and
breast cancer cells (20, 21). In breast cancer cells, activation of
MAPK was tyrosine kinase- and Ras-dependent,
suggesting activation of a pathway similar to that employed by classic
growth factors (21). The existence of membrane estrogen receptors has
been known for 20 years (22), but only recently has their potential importance been appreciated. Both the classic estrogen receptor (ER- ) and a second isotype, ER- , are expressed in MC (23).
Accordingly, we wished to determine whether the ability of
17 -estradiol to inhibit MAPK activity in MC was receptor-mediated and whether cell surface or cytoplasmic receptors were most important. To address this question, we employed a specific estrogen receptor antagonist, ICI 182,780, and a cell-impermeable estrogenic agonist, 17 -estradiol/BSA. Co-incubation with ICI 182,780 (5 × 10 7 M) prevented the inhibitory actions of
17 -estradiol on p44/42 MAPK and SAPK activity in stretched cells
(Fig. 3, A and B),
indicating that 17 -estradiol acted through estrogen receptors.
Expression of estrogen receptor was not affected by 17 -estradiol
(Fig. 4). 17 -Estradiol/BSA had
significantly less inhibitory effect when compared with 17 -estradiol
(Fig. 5, A and B),
indicating that cell penetration was required for full inhibitory
actions of 17 -estradiol. Some ability to attenuate stretch-induced
p44/42 MAPK and SAPK activation was observed with 17 -estradiol/BSA, so we cannot exclude the possibility of a membrane receptor-mediated component in this circumstance. The importance of nonmembrane signaling
was emphasized, however, by our observations that 2 h of
preincubation with 17 -estradiol was unable to inhibit p44/42 MAPK
(Fig. 6) or SAPK (data not shown)
signaling in response to MC stretch.

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 3.
Stretch-induced p44/42 MAPK and SAPK activity
in MC is prevented by 17 -estradiol and
restored by ICI-182,780. A, serum-starved MC were
incubated with 17 -estradiol (10 8 M) in the
presence or absence of the specific estrogen receptor antagonist
ICI-182,780 (5 × 10 7 M) for 24 h
and then exposed to a 27-kPa stretch at 60 Hz for 10 min. p44/42 MAPK
activity in total cell lysate was assayed by in vitro
phosphorylation of a target Elk-1 protein and immunoblotting with an
antibody specifically recognizing phosphorylated Elk-1
(Ser383). These data are shown graphically below
(n = 3). B, MC were treated as in
A, and SAPK activity in total cell lysate was measured by
in vitro phosphorylation of a target c-Jun protein,
which was visualized by immunoblotting with an antibody specific for
phosphorylated c-Jun (Ser63). Total SAPK protein is
shown above. The data are shown graphically below
(n = 3).
|
|

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 4.
ER protein
expression is not affected by 17 -estradiol in
MC. Serum-starved MC were exposed to 17 -estradiol for 24 h, and ER protein expression was assessed by Western blot. Three
experiments are summarized below.
|
|

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 5.
Stretch-induced p44/42 MAPK and SAPK activity
in MC is completely prevented by 17 -estradiol
but not by 17 -estradiol/BSA.
A, serum-starved MC were incubated with 17 -estradiol
(10 8 M) in the presence or absence of the
membrane-impermeant estrogen 17 -estradiol/BSA (10 8
M) for 24 h and then exposed to a 27-kPa stretch at 60 Hz for 10 min. p44/42 MAPK activity in total cell lysate was assayed by
in vitro phosphorylation of a target Elk-1 protein and
immunoblotting with an antibody specifically recognizing phosphorylated
Elk-1 (Ser383). Total p44/42 MAPK is shown
above, and results are summarized below
(n = 3). B, MC were treated as in
A, and SAPK activity in total cell lysate was measured by
in vitro phosphorylation of a target c-Jun protein,
which was visualized by immunoblotting with an antibody specific for
phosphorylated c-Jun (Ser63). Total SAPK protein is
shown above. Data are shown graphically below
(n = 3).
|
|

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 6.
Stretch-induced p44/42 MAPK phosphorylation
in MC is not prevented by short term incubation with
17 -estradiol. Serum-starved MC were
incubated with 17 -estradiol (10 8 M) for
2 h and then exposed to a 27-kPa stretch at 60 Hz for 10 min.
p44/42 MAPK phosphorylation was measured by Western blot with an
antibody specifically recognizing phosphorylated extracellular
signal-regulated kinase (Thr202/Tyr204).
|
|
Estrogen Prevents Strain-induced MAPK Nuclear Localization--
We
have observed prompt nuclear localization of phosphorylated MAPK
proteins in response to stretch (12, 24). Consequently, we sought to
determine whether 17 -estradiol would prevent nuclear localization of
phospho-MAPKs and whether this was a receptor-mediated event. Figs.
7 and 8
demonstrate that stretch-induced p44/42 MAPK and SAPK activation and
nuclear localization are prevented by preincubation with
10 8 M 17 -estradiol. The addition of the
specific estrogen receptor antagonist ICI 182,780 (5 × 10 7 M) restored activation and nuclear
localization of phospho-MAPKs, indicating that the inhibitory effect of
estrogen resides in receptor-mediated actions.

View larger version (119K):
[in this window]
[in a new window]
|
Fig. 7.
ICI-182,780 restores stretch-induced
phospho-p44/42 MAPK nuclear translocation in MC treated with
17 -estradiol. MC were incubated with
anti-phospho-p44/42 MAPK, washed, incubated with a goat anti-rabbit IgG
conjugate, and then visualized using confocal microscopy. Unstretched
cells (A) show only light nuclear staining. Application of
27-kPa stretch at 60 Hz for 10 min led to prompt induction and nuclear
translocation of phospho-p44/42 MAPK (B). This was
completely prevented by preincubation with 17 -estradiol
(10 8 M, 24 h) (C).
Co-incubation with ICI-182,780 (5 × 10 7
M, 24 h) restored the stretch-induced nuclear
translocation (D).
|
|

View larger version (75K):
[in this window]
[in a new window]
|
Fig. 8.
ICI-182,780 restores stretch-induced
phospho-SAPK nuclear translocation in MC treated with
17 -estradiol. MC were incubated with
anti-phospho-SAPK, washed, incubated with a goat anti-rabbit IgG
conjugate, and then visualized using confocal microscopy. Unstretched
cells (A) show only light nuclear staining. Application of
27-kPa stretch at 60 Hz for 10 min led to prompt induction and nuclear
translocation of phospho-SAPK (B). This was completely
prevented by preincubation with 17 -estradiol (10 8
M, 24 h) (C). Co-incubation with
ICI-182,780 (5 × 10 7 M, 24 h)
restored the stretch-induced nuclear translocation
(D).
|
|
Estrogen Prevents Strain-induced MAPK AP-1 Nuclear Protein
Binding--
p44/42 MAPK activation induces AP-1 nuclear protein
binding and transactivation of AP-1-containing consensus sequences in many situations (13), and acute estrogen exposure activated AP-1 in
resting MC (5). We have observed AP-1 nuclear protein binding in
stretched MC (12). Accordingly, we sought to determine the effect of
17 -estradiol on AP-1 nuclear protein binding in MC exposed to cyclic
strain. Preincubation with 10 8 M
17 -estradiol for 24 h prior to stretch substantially decreased AP-1 nuclear protein binding after 10 min of stretch (Fig.
9). Again, co-incubation with ICI 182,780 restored AP-1 binding, indicating the importance of the estrogen
receptor in this effect.

View larger version (96K):
[in this window]
[in a new window]
|
Fig. 9.
ICI-182,780 restores stretch-induced AP-1
nuclear protein binding in MC treated with
17 -estradiol. Extracted MC nuclear
proteins were reacted with radiolabeled AP-1 consensus
oligonucleotides, electrophoresed, and autoradiographed. A
representative autoradiograph is shown (n = 3).
Lane 1 shows nuclear protein binding in unstretched MC.
Application of 27-kPa stretch at 60 Hz for 10 min led to an increase in
nuclear protein binding (lane 2), and this was
prevented by preincubation with 17 -estradiol (10 8
M, 24 h) (lane 3). Co-incubation of
17 -estradiol with ICI-182,780 (5 × 10 7
M, 24 h) restored the AP-1 nuclear protein binding
(lane 4). Competition experiments with a 100-fold excess of
unlabeled AP-1 consensus oligonucleotides completely prevented AP-1
visualization (data not shown).
|
|
Estrogen Attenuates the Induction of c-fos in Response to
Strain--
Both p44/42 MAPK and SAPK signal to induce Fos and
Jun protein expression and thus AP-1 transactivational activity
(13). Indeed, increases in c-fos expression represented the
first important MC response to mechanical strain described (6).
Consequently, we sought to determine whether 17 -estradiol could
inhibit c-fos expression in stretched MC. Indeed,
preincubation for 24 h with 10 8 M
17 -estradiol abrogated the increase in c-fos expression
observed with RT-PCR after 2 h of cyclic strain (Fig.
10). ICI 182,780 blocked the inhibitory
effect of 17 -estradiol, indicating once again the importance of
estrogen receptors in mediating this effect.

View larger version (23K):
[in this window]
[in a new window]
|
Fig. 10.
ICI-182,780 restores stretch-induced
proto-oncogene expression in MC treated with
17 -estradiol. MC were incubated with
17 -estradiol (10 8 M) in the presence or
absence of the specific estrogen receptor antagonist ICI-182,780
(5 × 10 7 M) for 24 h and then
exposed to a 27-kPa stretch at 60 Hz for 10 min. c-fos and
-actin mRNA levels were assessed by semiquantitative RT-PCR. The
data are shown graphically below (n = 3).
|
|
Estrogen Does Not Disrupt Stretch-induced Cytoskeletal
Arrangement--
In recent work, we demonstrated that stretch-induced
p44/42 MAPK activation in MC was absolutely dependent on the presence of an intact actin cytoskeleton (12). Consequently, we sought to
determine whether the ability of 17 -estradiol to disrupt such activation rested in effects on the actin cytoskeleton. Phalloidin staining revealed prompt (10 min) formation of actin stress fibers in
stretched MC (Fig. 11). 17 -estradiol
did not inhibit such formation, indicating that its ability to block
stretch-induced MAPK activation did not rest in disruption of the actin
cytoskeleton or its rearrangement.

View larger version (90K):
[in this window]
[in a new window]
|
Fig. 11.
Stretch-induced actin stress fiber
organization in MC is not prevented by
17 -estradiol. Actin cytoskeletal
organization in MC was visualized by phalloidin staining and
confocal microscopy. Unstretched MC (A) show largely
nonparallel stress fibers, without a significant alteration after
incubation with 17 -estradiol (10 8 M) for
24 h (B). Application of stretch (27 kPa, 60 Hz for 10 min) results in the formation of intense stress fibers (C),
which are not disrupted by preincubation with 17 -estradiol
(D).
|
|
Estrogen Induces the Expression of MKP-1--
Dual specificity
phosphatases play a key role in the extent and duration of MAPK
activation. MKP-1, the prototype of the MAPK phosphatase family, is
known to inactivate both p44/42 MAPK and SAPK (25). As such, we
investigated the potential role of MKP-1 in mediating the effects of
estrogen in our system. MC incubation with 17 -estradiol
(10 8 and 10 7 M) for 24 h
resulted in an almost 2-fold increase in MKP-1 protein levels as seen
in Fig. 12A. Protein
expression of MKP-3, which has specific activity for phospho-p44/42
MAPK (26) was unaffected (Fig. 12B).

View larger version (16K):
[in this window]
[in a new window]
|
Fig. 12.
Effects of
17 -estradiol on MKP-1 and MKP-3
expression. Serum-starved MC were incubated with 17 -estradiol
at the indicated concentrations for 24 h. Total cell lysate was
immunoblotted with an antibody specifically recognizing MKP-1
(A), MKP-3 (B) or -actin. The graph below each
pair of blots summarizes the results of three independent experiments,
with normalization for protein loading to -actin.
|
|
 |
DISCUSSION |
In the best characterized animal model of chronic renal failure,
the subtotally nephrectomized rat, increased glomerular capillary pressure (as little as 20%) triggers MC responses that ultimately result in glomerulosclerosis (8, 27). However, it has been observed
that female rats subjected to subtotal nephrectomy suffer only a
fraction of the sclerotic injury observed in male rats (28). In support
of this, differences in glomerular hemodynamics have also been observed
in female rats, with a tendency to vasorelaxation (29).
The MC is central to the injurious glomerular response to
insults that result in progressive renal failure, such as subtotal nephrectomy. In vitro studies of the application of cyclic
mechanical strain to MC have demonstrated that this stimulus results in
MC proliferation (30) and production of collagenous protein (7), thus
mimicking the in vivo responses observed after increases in
intraglomerular pressure. We and others have repeatedly observed activation of MAPKs in response to either cyclic or static MC strain
and have shown such activation to signal proliferation and matrix
production (9, 11, 31, 32). Given the apparent protection
afforded by female gender to 5/6 nephrectomized rats, we hypothesized
that estrogen would limit MAPK activation in stretched MC and thus
prevent proliferation.
Indeed, the first major finding of the current study was that 24-h
preincubation with 17 -estradiol prevented the usual prompt activation of p44/42 MAPK and SAPK observed after the initiation of
strain. Similarly, the nuclear translocation of phosphorylated kinases
was also prevented. Tellingly, preincubation with 17 -estradiol for
2 h was unable to affect strain activation, suggesting that the
observed effect of estrogen was not an acute event but probably involved genomic actions. This was supported by two other observations, that inhibition of 17 -estradiol binding to receptors by ICI 182,780 restored MAPK activation in stretched cells and that a cell-impermeable estrogen agonist, 17 -estradiol/BSA, had significantly less
inhibitory effect on strain-induced MAPK signaling. These data indicate
that 17 -estradiol enters the cell and binds to cytoplasmic or
nuclear receptors to exert inhibitory actions on MAPK signaling.
A number of studies have examined the effect of estrogen on vascular
smooth muscle cells and MC, and estrogen has been shown to inhibit
serum and growth factor-induced p44/42 MAPK activity. In addition,
17 -estradiol limits tumor necrosis factor -induced SAPK
activation in chondrocytes. Interestingly, estrogen was found to
inhibit type I collagen synthesis in quiescent MC in response to
transforming growth factor- 1, an effect that is dependent on Sp1
(5). Our studies of the effects of 17 -estradiol on strain-induced
kinase activation in MC are in accord with these observations. Short
term studies have, however, also revealed that 17 -estradiol can
activate MAPKs (5). This effect was also observed with selective
estrogen receptor modulators (23). Although two or more peaks of MAPK
activity may occur in MC in response to some stimuli (33), we observed
only one peak of MAPK activation over 24 h of strain.
The two well established nuclear estrogen receptors, ER and ER ,
are known to exist in murine MC (23). The actions of ER after
ligation by estrogenic agonists such as 17 -estradiol are well
defined. One target of the activated nuclear ER is AP-1. An
interaction between the ER -estrogen complex can modify binding of
the Fos-Jun heterodimer to AP-1 consensus sequences (34). We have
demonstrated p44/42 MAPK-dependent induction of AP-1
nuclear protein binding in stretched MC (12). Consequently, we reasoned that 17 -estradiol might affect AP-1 nuclear protein binding to consensus sequences in stretched MC. Consistent with its inhibitory effects on p44/42 MAPK and SAPK activation, 17 -estradiol also prevented AP-1 nuclear protein binding in stretched MC. As expected, this effect depends on an interaction of 17 -estradiol with the ER,
since it could be prevented by ICI 182,780. Concordantly, c-fos induction in this setting was also inhibited by
17 -estradiol. We and others have shown that MAPK-AP-1 signaling is a
critical inducer of proliferation in stretched MC (9, 12, 35). The ability of 17 -estradiol to inhibit this signaling pathway was not
via up-regulation of ER , since incubation of MC with
10 8 17 -estradiol for 24 h did not affect ER
expression by Western blot.
We have demonstrated that stretch-induced MAPK activation depends on
the presence of an intact actin cytoskeleton (12). It has been observed
that estrogen leads to actin depolymerization in cervical epithelia
(36) and that cytoplasmic estrogen receptors may interact with
RhoGTPases (37). Consequently, we sought to determine whether the
ability of 17 -estradiol to prevent stretch-induced MAPK signaling in
MC was secondary to effects on the actin cytoskeleton. Phalloidin
staining revealed that actin stress fibers formed normally (within 10 min) in stretched MC in the presence of estrogen, indicating that other
mechanisms must account for estrogen's inhibition of MAPK signaling in
this setting.
Recently, Nuedling et al. (38) have shown that MKP-1 is
up-regulated by 17 -estradiol in unstretched cardiac myocytes, an effect seen as early as 30 min after stimulation and associated with a concurrent decrease in estrogen-mediated p44/42 MAPK activation in these cells. MKP-1 is the prototype of the MAPK dual specificity phosphatase family and may inactivate both p44/42 MAPK and SAPK (25).
Consequently, we investigated the effects of 17 -estradiol on MKP-1
expression in MC and found that 24-h incubation with 17 -estradiol
induced protein levels of MKP-1. No such effect was observed with the
phopsho-p44/42 MAPK-specific phosphatase MKP-3. Although additional
mechanisms may exist whereby 17 -estradiol inhibits stretch-induced
signaling in MC, this effect on MKP-1 may be responsible for the
attenuation of stretch-induced MAPK activation.
In summary, the data presented in this study suggest a mechanism by
which estrogen may exert protective effects in progressive renal
disease (i.e. through the inhibition of stretch-induced MAPK
activation). The inhibition of stretch-induced MAPK activation by
17 -estradiol is dependent on intracellular ER receptors and is
time-dependent. 17 -estradiol does not inhibit
strain-induced stress fiber formation of the actin cytoskeleton but
does increase base-line expression of MKP-1. Further studies will be
necessary to define the mechanism(s) whereby estrogen
up-regulates this dual specificity phosphatase.
 |
FOOTNOTES |
*
The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
§
Supported by a research fellowship from Bristol-Myers-Squibb
(Canada). To whom correspondence should be addressed: 13 EN-243, Toronto General Hospital, University Health Network, 200 Elizabeth St.,
Toronto, Ontario MUG 2C4, Canada. Tel.: 416-340-5093; Fax: 416-340-0029; E-mail: joan.krepinsky@utoronto.ca.
Supported by research funding from the Kidney Foundation of Canada.
**
Supported by research funding from the Canadian Institutes of
Health Research.
Published, JBC Papers in Press, January 2, 2002, DOI 10.1074/jbc.M106670200
 |
ABBREVIATIONS |
The abbreviations used are:
MAPK, mitogen-activated protein kinase;
MC, mesangial cell(s);
kPa, kilopascals;
BSA, bovine serum albumin;
SAPK, stress-activated protein
kinase;
DTT, dithiothreitol;
ER, estrogen receptor;
PBS, phosphate-buffered saline;
RT, reverse transcriptase.
 |
REFERENCES |
| 1.
|
Brenner, B. M.
(1985)
Am. J. Physiol.
249,
F324-F337[Abstract/Free Full Text]
|
| 2.
|
Anderson, S.,
Meyer, T. W.,
Rennke, H. G.,
and Brenner, B. M.
(1985)
J. Clin. Invest.
76,
612-619
|
| 3.
|
Silbiger, S. R.,
and Neugarten, J.
(1995)
Am. J. Kidney Dis.
25,
515-533[Medline]
[Order article via Infotrieve]
|
| 4.
|
Kwan, G.,
Neugarten, J.,
Sherman, M.,
Ding, Q.,
Fotadar, U.,
Lei, J.,
and Silbiger, S.
(1996)
Kidney Int.
50,
1173-1179[Medline]
[Order article via Infotrieve]
|
| 5.
|
Neugarten, J.,
Medve, I.,
Lei, J.,
and Silbiger, S. R.
(1999)
Am. J. Physiol.
277,
F875-F881[Abstract/Free Full Text]
|
| 6.
|
Akai, Y.,
Homma, T.,
Burns, K. D.,
Yasuda, T.,
Badr, K. F.,
and Harris, R. C.
(1994)
Am. J. Physiol.
267,
C482-C490[Abstract/Free Full Text]
|
| 7.
|
Harris, R. C.,
Haralson, M. A.,
and Badr, K. F.
(1992)
Lab. Invest.
66,
548-554[Medline]
[Order article via Infotrieve]
|
| 8.
|
Riser, B. L.,
Cortes, P.,
Zhao, X.,
Bernstein, J.,
Dumler, F.,
and Narins, R. G.
(1992)
J. Clin. Invest.
90,
1932-1943
|
| 9.
|
Kawata, Y.,
Mizukami, Y.,
Fujii, Z.,
Sakamura, T.,
Yoshida, K.,
and Matsuzaki, M.
(1998)
J. Biol. Chem.
273,
16905-16912[Abstract/Free Full Text]
|
| 10.
|
Ingram, A.,
Thai, K., Ly, H.,
Kang, M.,
and Scholey, J. W.
(1999)
Kidney Int.
55,
476-485[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Ingram, A. J.,
James, L., Ly, H.,
Thai, K.,
Cai, L.,
and Scholey, J. W.
(2000)
Kidney Int.
58,
1067-1077[CrossRef][Medline]
[Order article via Infotrieve]
|
| 12.
|
Ingram, A. J.,
James, L.,
Cai, L.,
Thai, K., Ly, H.,
and Scholey, J. W.
(2000)
J. Biol. Chem.
275,
40301-40306[Abstract/Free Full Text]
|
| 13.
|
Karin, M.
(1995)
J. Biol. Chem.
270,
16483-16486[Free Full Text]
|
| 14.
|
Hamaguchi, A.,
Kim, S.,
Yano, M.,
Yamanaka, S.,
and Iwao, H.
(1998)
J. Am. Soc. Nephrol.
9,
372-380[Abstract]
|
| 15.
|
Kim, S. J.,
Angel, P.,
Lafyatis, R.,
Hattori, K.,
Kim, K. Y.,
Sporn, M. B.,
Karin, M.,
and Roberts, A. B.
(1990)
Mol. Cell. Biol.
10,
1492-1497[Abstract/Free Full Text]
|
| 16.
|
Chomczynski, P.,
and Sacchi, N.
(1987)
Anal. Biochem.
162,
156-159[Medline]
[Order article via Infotrieve]
|
| 17.
|
Ingram, A.,
Parbtani, A.,
Thai, K., Ly, H.,
Shankland, S. J.,
Morrissey, G.,
and Scholey, J. W.
(1995)
Kidney Int.
48,
1857-1865[Medline]
[Order article via Infotrieve]
|
| 18.
|
Chen, Z.,
Yuhanna, I. S.,
Galcheva-Gargova, Z.,
Karas, R. H.,
Mendelsohn, M. E.,
and Shaul, P. W.
(1999)
J. Clin. Invest.
103,
401-406[Medline]
[Order article via Infotrieve]
|
| 19.
|
Goetz, R. M.,
Thatte, H. S.,
Prabhakar, P.,
Cho, M. R.,
Michel, T.,
and Golan, D. E.
(1999)
Proc. Natl. Acad. Sci. U. S. A.
96,
2788-2793[Abstract/Free Full Text]
|
| 20.
|
Singer, C. A.,
Figueroa-Masot, X. A.,
Batchelor, R. H.,
and Dorsa, D. M.
(1999)
J. Neurosci.
19,
2455-2463[Abstract/Free Full Text]
|
| 21.
|
Migliaccio, A., Di,
Domenico, M.,
Castoria, G.,
de Falco, A.,
Bontempo, P.,
Nola, E.,
and Auricchio, F.
(1996)
EMBO J.
15,
1292-1300[Medline]
[Order article via Infotrieve]
|
| 22.
|
Pietras, R. J.,
and Szego, C. M.
(1977)
Nature
265,
69-72[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Neugarten, J.,
Acharya, A.,
Lei, J.,
and Silbiger, S.
(2000)
Am. J. Physiol.
279,
F309-F318[Abstract/Free Full Text]
|
| 24.
|
Ingram, A. J.,
James, L.,
Thai, K., Ly, H.,
Cai, L.,
and Scholey, J. W.
(2000)
Am. J. Physiol.
279,
F243-F251[Abstract/Free Full Text]
|
| 25.
|
Haneda, M.,
Sugimoto, T.,
and Kikkawa, R.
(1999)
Eur. J. Pharmacol.
365,
1-7[CrossRef][Medline]
[Order article via Infotrieve]
|
| 26.
|
Muda, M.,
Theodosiou, A.,
Rodrigues, N.,
Boschert, U.,
Camps, M.,
Gillieron, C.,
Davies, K.,
Ashworth, A.,
and Arkinstall, S.
(1996)
J. Biol. Chem.
271,
27205-27208[Abstract/Free Full Text]
|
| 27.
|
Yasuda, T.,
Kondo, S.,
Homma, T.,
and Harris, R. C.
(1996)
J. Clin. Invest.
98,
1991-2000[Medline]
[Order article via Infotrieve]
|
| 28.
|
Lombet, J. R.,
Adler, S. G.,
Anderson, P. S.,
Nast, C. C.,
Olsen, D. R.,
and Glassock, R. J.
(1989)
J. Lab. Clin. Med.
114,
66-74[Medline]
[Order article via Infotrieve]
|
| 29.
|
Munger, K.,
and Baylis, C.
(1988)
Am. J. Physiol.
254,
F223-F231[Abstract/Free Full Text]
|
| 30.
|
Harris, R. C.,
Akai, Y.,
Yasuda, T.,
and Homma, T.
(1994)
Kidney Int. Suppl.
45,
17-21
|
| 31.
|
Ingram, A. J.,
James, L., Ly, H.,
Thai, K.,
and Scholey, J. W.
(2000)
Kidney Int.
58,
1431-1439[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Ishida, T.,
Haneda, M.,
Maeda, S.,
Koya, D.,
and Kikkawa, R.
(1999)
Diabetes
48,
595-602[Abstract]
|
| 33.
|
Bonacchi, A.,
Romagnani, P.,
Romanelli, R. G.,
Efsen, E.,
Annunziato, F.,
Lasagni, L.,
Francalanci, M.,
Serio, M.,
Laffi, G.,
Pinzani, M.,
Gentilini, P.,
and Marra, F.
(2001)
J. Biol. Chem.
276,
9945-9954[Abstract/Free Full Text]
|
| 34.
|
Umayahara, Y.,
Kawamori, R.,
Watada, H.,
Imano, E.,
Iwama, N.,
Morishima, T.,
Yamasaki, Y.,
Kajimoto, Y.,
and Kamada, T.
(1994)
J. Biol. Chem.
269,
16433-16442[Abstract/Free Full Text]
|
| 35.
|
Yasuda, T.,
Akai, Y.,
Kondo, S.,
Becker, B. N.,
Homma, T.,
Owada, S.,
Ishida, M.,
and Harris, R. C.
(1996)
Contrib. Nephrol.
118,
222-228[Medline]
[Order article via Infotrieve]
|
| 36.
|
Gorodeski, G. I.
(2000)
Am. J. Physiol. Cell Physiol.
279,
C2028-C2036[Abstract/Free Full Text]
|
| 37.
|
Su, L. F.,
Knoblauch, R.,
and Garabedian, M. J.
(2000)
J. Biol. Chem.
276,
3231-3237[Abstract/Free Full Text]
|
| 38.
|
Nuedling, S.,
Kahlert, S.,
Loebbert, K.,
Meyer, R.,
Vetter, H.,
and Grohe, C.
(1999)
FEBS Lett.
454,
271-276[CrossRef][Medline]
[Order article via Infotrieve]
|
Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.

CiteULike Complore Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
D. Wu, F. Peng, B. Zhang, A. J. Ingram, D. J. Kelly, R. E. Gilbert, B. Gao, and J. C. Krepinsky
PKC-{beta}1 Mediates Glucose-Induced Akt Activation and TGF-{beta}1 Upregulation in Mesangial Cells
J. Am. Soc. Nephrol.,
March 1, 2009;
20(3):
554 - 566.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Chiloeches, A. Sanchez-Pacheco, B. Gil-Araujo, A. Aranda, and M. Lasa
Thyroid Hormone-Mediated Activation of the ERK/Dual Specificity Phosphatase 1 Pathway Augments the Apoptosis of GH4C1 Cells by Down-Regulating Nuclear Factor-{kappa}B Activity
Mol. Endocrinol.,
November 1, 2008;
22(11):
2466 - 2480.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C. Baylis
Sexual Dimorphism of the Aging Kidney: Role of Nitric Oxide Deficiency
Physiology,
June 1, 2008;
23(3):
142 - 150.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Peng, D. Wu, B. Gao, A. J. Ingram, B. Zhang, K. Chorneyko, R. McKenzie, and J. C. Krepinsky
RhoA/Rho-Kinase Contribute to the Pathogenesis of Diabetic Renal Disease
Diabetes,
June 1, 2008;
57(6):
1683 - 1692.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
G. Y. Oudit, A. M. Herzenberg, Z. Kassiri, D. Wong, H. Reich, R. Khokha, M. A. Crackower, P. H. Backx, J. M. Penninger, and J. W. Scholey
Loss of Angiotensin-Converting Enzyme-2 Leads to the Late Development of Angiotensin II-Dependent Glomerulosclerosis
Am. J. Pathol.,
June 1, 2006;
168(6):
1808 - 1820.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. C. Krepinsky, Y. Li, Y. Chang, L. Liu, F. Peng, D. Wu, D. Tang, J. Scholey, and A. J. Ingram
Akt Mediates Mechanical Strain-Induced Collagen Production by Mesangial Cells
J. Am. Soc. Nephrol.,
June 1, 2005;
16(6):
1661 - 1672.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Dash, A. G Schmidt, A. Pathak, M. J Gerst, D. Biniakiewicz, V. J Kadambi, B. D Hoit, W. T Abraham, and E. G Kranias
Differential regulation of p38 mitogen-activated protein kinase mediates gender-dependent catecholamine-induced hypertrophy
Cardiovasc Res,
March 1, 2003;
57(3):
704 - 714.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
|
Advertisement
Advertisement
|